With shares of AstraZeneca (NASDAQ: AZN) returning 55% over the last three years, easily topping the market's return of 29%, it's no surprise why investors might be curious about whether there's more upside in store.

But is now the best time to buy the stock, given its upcoming catalysts and recent financial performance? Let's analyze one argument for why this opportunity is still ripe right now, then look at a counterargument.

The bull thesis for investing in AstraZeneca is that it's making a lot of big bets to ensure that its future will be more profitable than its recent past (which wasn't half bad).

Continue reading

Source Fool.com